Latest News
Web Date: January 25, 2016

Industry, Academia Join For U.K. Drug Development Fund

Collaboration: AstraZeneca, GSK, J&J combine with three universities to accelerate development of novel medicines
Department: Science & Technology
Keywords: England, universities, drug development, technology transfer, fund

AstraZeneca, GlaxoSmithKline, Johnson & Johnson and three U.K. universities—Imperial College London, University of Cambridge and University College London (UCL)—are combining to create an almost-$60 million investment fund for drug development.

The program, the Apollo Therapeutics Fund, aims to accelerate the translation of academic science into medicines. The partners plan to develop drugs for all therapy areas using systems including small molecules, peptides, proteins, antibodies, and cell and gene therapies.

The industrial partners will contribute close . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society